Vertex 809-110

A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Purpose: Roll Over study with Combination Therapy Ivacaftor and Lumacaftor in Children 6-11 for Cystic Fibrosis homozygote genotype DeltaF508. 

Sponsor: Vertex Pharmaceuticals

Principal Investigator: Cori Daines, MD

Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Study Status: 
Currently Enrolling